File size: 327kb | Date: 15 January 2020 | Clinical Statements - PDF
This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD (manufacturer of Nexplanon®) to healthcare professionals in the UK about updated guidance regarding the recommended Nexplanon® insertion site.
File size: 407kb | Date: 9 February 2021 | Clinical Statements - PDF
This statement is a response to a study published in the New England Journal of Medicine, suggests that a 52mg levonorgestrel-releasing intrauterine system (LNG-IUS) is non-inferior to a T380A copper IUD (Cu-IUD) for emergency contraception (EC).
File size: 378kb | Date: 8 February 2021 | Clinical Statements - PDF
This statement notes that the Levosert® 52mg LNG-IUS has been licensed for contraceptive use for 6 years. Levosert remains licensed for 5 years for management of heavy menstrual bleeding and is not licensed for endometrial protection as part of HRT.
File size: 232kb | Date: 2 February 2021 | Clinical Statements - PDF
This statement is a response to a new paper published in BMJ Evidence Based Medicine Journal suggesting that antibiotics may lessen the effectiveness of hormonal contraception.
File size: 196kb | Date: 18 December 2020 | Clinical Statements - PDF
This FSRH CEU Statement considers the risk of thromboembolism associated with Covid-19 infection, and suggests a pragmatic approach to use of combined hormonal contraception during the Covid-19 pandemic
File size: 209kb | Date: 23 November 2020 | Clinical Statements - PDF
The FSRH CEU summarizes and comments on the Cameron, et al “Bridge-It” study, which found that women receiving levonorgestrel emergency contraception from a pharmacy are more likely to be using effective ongoing contraception if they are given a three-month supply of progestogen-only pill and facilitated access to local SRH services.
File size: 233kb | Date: 17 November 2020 | Clinical Statements - PDF
“The effects on ovarian activity of delaying versus immediately restarting combined oral contraception after missing three pills and taking ulipristal acetate 30 mg”
The journal Contraception recently published a study investigating timing of combined oral contraceptive pill (COC) restart after missed pills and use of ulipristal acetate emergency contraception (UPA-EC). The FSRH CEU responds to this study and advises where guidance does—and does not—change.
File size: 189kb | Date: 13 July 2020 | Clinical Statements - PDF
This statement is a response to new advice from the MHRA regarding use of cyproterone acetate and risk of meningioma.
File size: 355kb | Date: 6 July 2020 | Clinical Statements - PDF
This statement addresses the issues faced by the health and care workforce before and during the COVID-19 pandemic.
File size: 246kb | Date: 9 April 2020 | Clinical Statements - PDF
FSRH CEU has produced an information sheet to support the provision of contraception by maternity services after childbirth during the Covid-19 outbreak.
File size: 396kb | Date: 20 March 2020 | Clinical Statements - PDF
At present, to reduce risk of coronavirus transmission, non-essential face-to-face contact with healthcare providers is being minimised where possible. Replacement procedures for long-acting reversible contraceptive (LARC) devices that have recently expired are non-essential.
This FSRH CEU statement provides recommendation on extended use of the etonogestrel implant and 52mg levonorgestrel-releasing intrauterine system during COVID restrictions.